Education
About Us
Working with TipRanks
Follow Us
OncoCyte Corp (OCX)
NASDAQ:OCX
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.39Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 22.42%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call conveyed a cautiously optimistic outlook, with significant progress in clinical trials and strong interest from transplant centers and pharma partners. However, challenges remain in managing revenue volatility and cash burn.Company Guidance
During OncoCyte's First Quarter 2025 Results call, the company outlined key guidance and metrics for the fiscal year. Their primary objectives include finalizing the clinical assay and trial design, completing a clinical trial to submit a data package to the FDA by the end of 2025, and ramping up revenue in 2026 by signing transplant centers for their research use-only kit. OncoCyte aims to have 20 sites trained on their GraftAssure workflow by the end of 2025, expanding from the 10 sites currently using their RUO assay across the U.S., Germany, U.K., Switzerland, Austria, and Southeast Asia. The company achieved central IRB approval for their clinical trial and anticipates participation from at least 3 of the top 10 U.S. transplant centers. Additionally, OncoCyte reported Q1 pharma services revenue of $2.1 million, with gross margins at 62%, and ended the quarter with nearly $33 million in cash. The company targets a cash burn rate of approximately $6 million per quarter until their commercial launch next year.Central IRB Approval for Clinical Trial
OncoCyte finalized their clinical trial design and received central IRB approval, marking a key milestone in safety and ethics review for their trial.
Strong Revenue from Pharma Services
Pharma services revenue of $2.1 million exceeded expectations, with gross margins of 62%. A large order late in the quarter enabled invoicing of $1.4 million.
Interest from Top Transplant Centers
OncoCyte expects to welcome at least 3 of the top 10 U.S. transplant centers as clinical trial participants, representing nearly 10% of U.S. transplant volumes.
Global Expansion of RUO Sites
10 sites are currently running OncoCyte's RUO assay in the U.S., Germany, U.K., Switzerland, Austria, and Southeast Asia.
Digital PCR Differentiation
OncoCyte is proving the value of digital PCR as a technology differentiator, offering simpler, faster, and cost-effective solutions compared to NGS.
Positive Feedback on DetermaIO
DetermaIO is showing promise in the drug rescue category, with potential partners expressing admiration for the results.
Strong Cash Position
OncoCyte concluded the first quarter with nearly $33 million in cash, including restricted cash to be accessed later this year.
OCX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OCX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $2.81 | $2.77 | -1.42% |
Mar 24, 2025 | $3.33 | $3.04 | -8.71% |
Nov 12, 2024 | $3.00 | $2.94 | -2.00% |
Aug 08, 2024 | $3.08 | $3.12 | +1.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does OncoCyte Corp (OCX) report earnings?
OncoCyte Corp (OCX) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is OncoCyte Corp (OCX) earnings time?
OncoCyte Corp (OCX) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OCX EPS forecast?
OCX EPS forecast for the fiscal quarter 2025 (Q2) is -0.23.